

Nab-sirolimus AMPECT

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Not qualified for an ESMO-MCBS credit



Serious and disabling adverse effects



Other adjustments



Nab-sirolimus AMPECT

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response



Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Sarcoma  
 Therapeutic Indication: Nab-sirolimus for the efficacy in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa).  
 Experimental Arm: Nab-sirolimus  
 Control Arm: Single arm

